The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
Open accessAbstract
In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [177Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [177Lu]Lu-PSMA-617 was demonstrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M., Bauder-Wüst, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 612
Self-citationHennrich, U., & Kopka, K. (2019) · Pharmaceuticals · doi:10.3390/ph12030114 · Cited by 440
Self-citationAfshar-Oromieh, A., Hetzheim, H., Kratochwil, C., Benesova, M., Eder, M., Neels, O. C., Eisenhut, M., Kübler, W., Holland-Letz, T., Giesel, F. L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161299 · Cited by 427
Self-citation(1993) · Biotechnology Advances · doi:10.1016/0734-9750(93)90273-p · Cited by 378
Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.227 · Cited by 305
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
Feuerecker, B., Tauber, R., Knorr, K., Heck, M., Beheshti, A., Seidl, C., Bruchertseifer, F., Pickhard, A., Gafita, A., Kratochwil, C., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.11.013 · Cited by 277
Benešová, M., Bauder-Wüst, U., Schäfer, M., Klika, K. D., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01210 · Cited by 228
Self-citationSchuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Müller, D., & Baum, R. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262713 · Cited by 187
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Hennrich, U., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13030038 · Cited by 184
Self-citationBarinka, C., Byun, Y., Dusich, C. L., Banerjee, S. R., Chen, Y., Castanares, M., Kozikowski, A. P., Mease, R. C., Pomper, M. G., & Lubkowski, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800765e · Cited by 180
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Hennrich, U., & Eder, M. (2021) · Pharmaceuticals · doi:10.3390/ph14080713 · Cited by 171
Self-citationCrystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Pomper, M. G., Musachio, J. L., Zhang, J., Scheffel, U., Zhou, Y., Hilton, J., Maini, A., Dannals, R. F., Wong, D. F., & Kozikowski, A. P. (2002) · Molecular Imaging · doi:10.1162/153535002320162750 · Cited by 138
Uijen, M. J. M., Derks, Y. H. W., Merkx, R. I. J., Schilham, M. G. M., Roosen, J. U., Privé, B. M., van Lith, S. A. M., van Herpen, C. M. L., Gotthardt, M., Heskamp, S., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05433-w · Cited by 137
Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Seifert, R., Kessel, K., Bögemann, M., Kulkarni, H., Zhang, J., Gerke, C., Fimmers, R., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04797-9 · Cited by 128
External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies
Kurth, J., Krause, B. J., Schwarzenböck, S. M., Stegger, L., Schäfers, M. A., & Rahbar, K. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0386-4 · Cited by 109
Khreish, F., Ghazal, Z., Marlowe, R. J., Rosar, F., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05525-7 · Cited by 107
Heynickx, N., Herrmann, K., Vermeulen, K., Baatout, S., & Aerts, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.04.003 · Cited by 106
Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05471-4 · Cited by 88
Challenges and future options for the production of lutetium-177
Vogel, W. V., van der Marck, S. C., & Versleijen, M. W. J. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05392-2 · Cited by 82
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
Barca, C., Griessinger, C. M., Faust, A., Depke, D. A., Essler, M., Windhorst, A. D., Devoogdt, N., Brindle, K. M., Schäfers, M. A., Zinnhardt, B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph15010013 · Cited by 78
Satapathy, S., Mittal, B. R., Sood, A. K., Das, C. K., Mavuduru, R. S., Goyal, S., Shukla, J., & Singh, S. K. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05618-3 · Cited by 60
Calais, J., Gafita, A., Eiber, M., Armstrong, W. R., Gartmann, J., Thin, P., Nguyen, K., Lok, V. M., Gosa, L., Grogan, T., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261982 · Cited by 50
Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management
Roscher, M., Bakos, G., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13040076 · Cited by 47
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Bögemann, M., & Rahbar, K. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04703-3 · Cited by 46
Calais, J., Czernin, J. G., Thin, P., Gartmann, J., Nguyen, K., Armstrong, W. R., Allen-Auerbach, M., Quon, A. S. W., Bahri, S., Gupta, P. K., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262543 · Cited by 41
Wichmann, C. W., Ackermann, U., Poniger, S. S., Young, K., Nguyen, B., Chan, G., Sachinidis, J. I., & Scott, A. M. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3889 · Cited by 31
Kind, F., Fassbender, T. F., Andrieux, G., Boerries, M., Meyer, P. T., & Ruf, J. (2021) · Cancers · doi:10.3390/cancers14010149 · Cited by 24
Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
Lau, J., Lee, H., Rousseau, J., Bénard, F., & Lin, K. (2022) · Molecules · doi:10.3390/molecules27154959 · Cited by 22
Herrmann, K., Rahbar, K., Eiber, M., Krause, B. J., Laßmann, M., Jentzen, W., Blumenstein, L., Klein, P. J., Basque, J., & Kurth, J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.097 · Cited by 20
Nuclear Medicine Beyond VISION
Fendler, W. P., Herrmann, K., & Eiber, M. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262441 · Cited by 10
Cited by
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Metadata
- Authors
- Hennrich, U., & Eder, M.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-10-20
- Volume
- 15
- Issue
- 10
- Pages
- 1292
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4306936773
- Cited by
- 318
- References
- 36
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.